-+ 0.00%
-+ 0.00%
-+ 0.00%

Molecular Partners Says MP0632 Preclinical Data At SITC 2026 Show No Detectable Impact On Healthy Mesothelial Or Epithelial Cells, Supporting IND-Enabling Studies In MSLN And EpCAM Solid Tumors

Benzinga·11/06/2026 06:14:00
Listen to the news
  • Logic-gated Switch-DARPin design enables potent, selective cytotoxicity against cells co-expressing tumor-associated antigens (TAAs) previously considered undruggable for T cell engagers
  • Favorable safety profile, with new data indicating healthy tissues expressing either TAA remain intact
  • Attractive therapeutic window underlines MP0632’s readiness for IND-enabling studies in solid tumors co-expressing MSLN and EpCAM